Ocular Biodistribution of <sup>89</sup>Zr-Bevacizumab in New Zealand Rabbits Determined Using PET/MRI: A Feasibility Study
| Author | Xiaoyuan Liu | en |
| Author | Jianqiang Ye | en |
| Author | Yan Zhang | en |
| Author | Quan Liu | en |
| Author | Ruizhen Bai | en |
| Author | Wenbo Yuan | en |
| Author | Dongyan Cai | en |
| Author | Xiaoyuan Zheng | en |
| Author | Yun Bian | en |
| Author | Shijun Zhou | en |
| Author | Juan Lv | en |
| Author | Yongjuan Ding | en |
| Author | Fen Xie | en |
| Author | Hongwen Lu | en |
| Author | Bingxue Xie | en |
| Issued Date | 2019-01-23 | en |
| Abstract | Background: Despite studies on positron emission tomography/magnetic resonance imaging (PET/MRI) in oncological imaging with high soft-tissue contrast resolution, PET/MRI has not been studied in ophthalmology. 89Zr-bevacizumab, designed as a probe for PET, targets vascular endothelial growth factor, which is highly expressed in ocular angiogenesis. Intravitreal injections of bevacizumab agents have curative effects on ocular disease. Objectives: To study the ocular biodistribution of 89Zr-bevacizumab in New Zealand rabbits using PET/MRI. Materials and Methods: 89Zr-bevacizumab, synthesized from conjugated bevacizumab and 89Zr-oxalate, and the purity of radiolabeled antibodies were determined using radio high-performance liquid chromatography (radio-HPLC). Instant thin-layer chromatography (ITLC) was utilized to differentiate the labeled product from aggregates and unlabeled 89Zr. 89Zr-bevacizumab was injected 2 mm from the left limbus into the vitreous humor of six normal New Zealand white rabbits. Micro-PET was utilized for dynamic imaging from 5 minutes to 60 minutes postinjection and for static imaging at 4 hours, 24 hours, 48 hours, 120 hours, and 144 hours (10-minutes scans) postinjection. PET/MRI scans were fused using PMOD software. Results: 89Zr-bevacizumab with a radiochemical purity of 93.21% was monitored via PET imaging. Radioactivity levels in the eyes plateaued approximately 5 minutes after administration of 89Zr-bevacizumab, and the measured vitreous values decreased from 340.52 ± 41.6% injected dose (ID)/g to 21.53 ± 3.39%ID/g by 144 hours. The half-life of the drug in the eye was calculated for 84.25 hours. Conclusion: 89Zr-bevacizumab could be monitored in animals by PET imaging, and the radiolabel exhibited high sensitivity in the vitreous body. Radioactivity levels in the eyes plateaued approximately 5 minutes after administration. This study clearly demonstrates the biodistribution of 89Zr-bevacizumab. | en |
| DOI | https://doi.org/10.5812/iranjradiol.68697 | en |
| Keyword | <sup>89</sup>Zr-Bevacizumab | en |
| Keyword | PET-MRI | en |
| Keyword | Eye | en |
| Keyword | Distribution | en |
| Publisher | Brieflands | en |
| Title | Ocular Biodistribution of <sup>89</sup>Zr-Bevacizumab in New Zealand Rabbits Determined Using PET/MRI: A Feasibility Study | en |
| Type | Research Article | en |